SCHEDULE: Madison Avenue Group Holds 17.7% Stake in Theravance Biopharma

Madison Avenue International LP, along with affiliated entities, has reported a beneficial ownership of 9,212,252 ordinary shares, representing 17.7% of Theravance Biopharma, Inc.

Summary

• Madison Avenue International LP, and its related entities (collectively, the 'Reporting Persons'), have filed a Schedule 13G, indicating their beneficial ownership of Theravance Biopharma, Inc. ordinary shares.
• As of June 30, 2026, the Reporting Persons collectively beneficially owned 9,212,252 ordinary shares.
• This ownership stake represents approximately 17.7% of the company's outstanding ordinary shares, based on 51,918,754 shares outstanding as of July 31, 2026.
• The filing details the reporting structure, with Madison Avenue Partners, LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC, and Eli Samaha being deemed beneficial owners due to their relationships with Madison Avenue International LP.
• Eli Samaha is identified as a key individual, holding various managerial and ownership roles across the reporting entities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but stable ownership stake without immediate indications of aggressive action or distress.

Positives

• Significant ownership stake of 17.7% indicates substantial investor confidence or strategic interest in Theravance Biopharma.
• The filing is an amendment to a previous Schedule 13G, suggesting a stable, ongoing relationship with the company rather than a new, potentially disruptive investment.
• The reporting structure is clearly defined, providing transparency regarding the beneficial ownership of a large block of shares.

Negatives

• The filing does not provide specific details on the investment strategy or future intentions of the Reporting Persons beyond maintaining their stake.
• The ownership percentage, while significant, does not represent a controlling interest, limiting immediate influence on company direction.

Risks

• While not explicitly stated as a risk in this filing, any significant disposition of shares by these large holders could negatively impact the stock price.
• The concentration of ownership among a few related entities could lead to coordinated actions that may not align with the interests of all shareholders.

Future Outlook

This filing is primarily a disclosure of ownership and does not contain forward-looking statements or specific guidance from the company regarding its future performance.

Management Comments

• The filing includes a certification by the Reporting Persons that the securities were not acquired or held for the purpose of influencing control of the issuer, other than in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that significant institutional ownership, as reported in Schedule 13G filings, is common in the biopharmaceutical sector. Such filings provide transparency on major shareholders who may influence corporate strategy or act as potential catalysts for change.

Comparison to Industry Standards

• Ownership stakes of 17.7% are substantial and not uncommon for activist investors or large institutional holders in the biotechnology and pharmaceutical industries.
• Companies like Moderna, BioNTech, and Gilead Sciences often see similar levels of institutional ownership reported in their respective filings.
• The reporting structure involving multiple related entities is a standard practice for investment funds to manage and report their holdings efficiently.

Stakeholder Impact

• Shareholders: The significant stake held by Madison Avenue International LP and its affiliates may influence future corporate actions or strategic decisions, potentially impacting shareholder value.
• Management: The substantial ownership may lead to increased scrutiny or engagement from the Reporting Persons regarding company strategy and performance.

Next Steps

• The Reporting Persons will continue to monitor their investment in Theravance Biopharma.
• Future filings will be made if there are material changes in beneficial ownership or other reportable events.

Key Dates

Keywords

Theravance Biopharma, Schedule 13G, Madison Avenue International LP, Beneficial Ownership, Ordinary Shares, Investment Management, SEC Filing